Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial inves

Trial Details

NCT ID
NCT05597345
Phase
PHASE2
Sponsor
University of Rochester
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Selinexor
Locations (sample)
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Age \>/= 18 years
  • Histologically confirmed diagnosis of SMM according to the IMWG definition: serum M-protein \>/= 3 g/dL or BMPC \>10% but \<60%, or both.
  • Should not meet CRAB criteria: hypercalcemia, anemia, bone lesions, or renal insufficiency thought to be related to the plasma cell disorder.
  • Should have 1 of the following risk factors to be considered intermediate risk and 2 or more risk factors to be considered high-risk:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →